Renascience

Renascience FCF Yield

The Free Cash Flow Yield of Renascience (4889.T) as of Nov 19, 2026 is -1.20 %. In the previous year, Free Cash Flow Yield was -0.73 % — a change of 64.45% (lower).

FCF Yield

-1.20 %

YoY

64.45%

Last updated:

Free Cash Flow Yield of Renascience is 2026 -1.20 % . Free Cash Flow Yield of Renascience was 2025 -0.73 % . It decreases by 64.45% lower compared to the previous year.

The Renascience FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2020
-0.74 JPY
Jan 1, 2021
-0.37 JPY
Jan 1, 2022
-0.96 JPY
Jan 1, 2023
-1.19 JPY
Jan 1, 2024
-0.96 JPY
Jan 1, 2025
-0.73 JPY
Jan 1, 2026
-1.20 JPY
The Renascience FCF Yield history
YEARFCF YieldYoY
-1.20 %+64.45%
-0.73 %-23.68%
-0.96 %-19.09%
-1.19 %+23.83%
-0.96 %+156.64%
-0.37 %-49.38%
-0.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Free Cash Flow Yield of Renascience is -1.20 % in 2026.

Free Cash Flow Yield of Renascience changed from -0.73 % to -1.20 %, representing a 64.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Renascience since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Renascience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Renascience

All Key Metrics — Renascience